إعلان
إعلان
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
24.27
USDبرعاية
-1.04
-4.12%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
24.65
+0.39
+1.59%
تقارير أرباح GLUE
النسبة الإيجابية المفاجئة
GLUE تفوق 14 من 18 آخر التقديرات.
78%
التقرير التالي
بيانات التقرير القادم
١٨ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$15.82M
/-$0.33
التغير الضمني من Q3 25 (Revenue/ EPS)
+23.87%
/--
التغير الضمني من Q4 24 (Revenue/ EPS)
-73.92%
/-243.48%
Monte Rosa Therapeutics, Inc. Common Stock earnings per share and revenue
On ٠٦ نوفمبر ٢٠٢٥, GLUE reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.38 USD, resulting in a 13.20% surprise. Revenue reached 12.77 مليون, compared to an expected 5.53 مليون, with a 130.95% difference. The market reacted with a +5.69% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 المحللين forecast an EPS of -0.33 USD, with revenue projected to reach 15.82 مليون USD, implying an زيادة of 0.00% EPS, and زيادة of 23.87% in Revenue from the last quarter.
الأسئلة الشائعة
What were Monte Rosa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Monte Rosa Therapeutics, Inc. Common Stock reported EPS of -$0.33, beating estimates by 13.2%, and revenue of $12.77M, 130.95% above expectations.
How did the market react to Monte Rosa Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 5.69%, changed from $12.31 before the earnings release to $13.01 the day after.
When is Monte Rosa Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ١٨ مارس ٢٠٢٦.
What are the forecasts for Monte Rosa Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
المحللين, Monte Rosa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of $15.82M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان